文献速递临床试验与 GCP流行病学与生物统计

改进分配规则提升持续再评估法的安全性

Improving safety of the continual reassessment method via a modified allocation rule.
PubMed 文献 · Stat Med · 2019-12-20

本文针对I期剂量递增试验中最大耐受剂量(MTD)的寻找,提出一种新的患者分配准则,通过仅增加一个直观参数来平衡MTD估计精度与毒性事件数量。将该准则融入单参数贝叶斯持续再评估法(CRM)的模拟显示,其平均精度与原设计相近但毒性反应更少;与过量控制递增等设计相比,可在相同精度下减少毒性反应或在相同毒性反应数下提高精度。

要点

  • 新分配准则需指定一个直观参数,可显式平衡MTD估计精度与毒性负担。
  • 融入单参数贝叶斯CRM后,模拟显示平均精度与原设计相近但毒性反应更少。
  • 与EWOC等设计相比,可在精度与毒性反应数之间取得更优权衡。

核心结论

  • 新分配准则使I期剂量递增设计在MTD估计精度与患者毒性反应数之间取得更好权衡,较部分现有方法更符合伦理。

研究设计与样本

  • 方法学研究:提出新分配准则并融入单参数贝叶斯持续再评估法(CRM),通过模拟比较其与原始设计及其他基于模型的剂量递增设计。

主要发现

  • 融入新准则的CRM平均精度与原设计相近,但平均毒性反应更少。
  • 与过量控制递增(EWOC)及其修改版相比,新设计可在相同平均精度下减少毒性反应,或在相同毒性反应数下提高平均精度。
  • 新准则仅需指定一个具有简单直观解释的额外参数。

临床怎么用

  • 在I期剂量递增试验设计阶段,可考虑采用该分配准则以在保持MTD估计精度的同时降低患者暴露于毒性剂量的风险。

局限性

  • 主要证据来自模拟研究,尚未在真实临床试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This article proposes a novel criterion for the allocation of patients in phase I dose-escalation clinical trials, aiming to find the maximum tolerated dose (MTD). Conventionally, using a model-based approach, the next patient is allocated to the dose with the toxicity estimate closest (in terms of the absolute or squared distance) to the maximum acceptable toxicity. This approach, however, ignores the uncertainty in point estimates and ethical concerns of assigning a lot of patients to overly toxic doses. In fact, balancing the trade-off between how accurately the MTD can be estimated and how many patients would experience adverse events is one of the primary challenges in phase I studies. Motivated by recent discussions in the theory of estimation in restricted parameter spaces, we propose a criterion that allows to balance these explicitly. The criterion requires a specification of one additional parameter only that has a simple and intuitive interpretation. We incorporate the proposed criterion into the one-parameter Bayesian continual reassessment method and show, using simulations, that it can result in similar accuracy on average as the original design, but with fewer toxic responses on average. A comparison with other model-based dose-escalation designs, such as escalation with overdose control and its modifications, demonstrates that the proposed design can result in either the same mean accuracy as alternatives but fewer toxic responses or in a higher mean accuracy but the same number of toxic responses. Therefore, the proposed design can provide a better trade-off between the accuracy and the number of patients experiencing adverse events, making the design a more ethical alternative over some of the existing methods for phase I trials.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Mozgunov P, Jaki T. Improving safety of the continual reassessment method via a modified allocation rule. Stat Med. 2019. PMID: 31859399. doi:10.1002/sim.8450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。